| Popis: |
The anthracyclines are an effective new class of antitumor antibiotics. Adriamycin (ADM) is the most extensively investigated member of this class. In addition to its clinically advantageous tumor cell toxicity (TCT), it exhibits diverse biologic actions. These include unwanted side toxicities which limit its usefulness. The exact mechanisms by which ADM exerts both TCT and side toxicities remain to be elucidated. In the past three or four years, much interest has been generated concerning the possible involvement of ADM radicals (ADM·) in these toxicities. This interest has been fueled by the realizations that ADM is activated to ADM· throughout biologic systems, that ADM side toxicities can be inhibited by a number of antioxidants, and that ADM-stimulated radical formation produces DNA damage. |
